Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$31.32
-3.1%		$33.08
$22.24
▼
$46.00
$1.93B0.631.20 million shs952,660 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$13.28
-4.8%		$15.65
$12.94
▼
$21.50
$1.81B2.14237,865 shs615,686 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.33
-8.6%		$1.68
$1.30
▼
$3.48
$439.88M1.771.72 million shs1.66 million shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$120.30
-5.5%		$145.44
$68.96
▼
$161.38
$1.83B-0.27250,323 shs179,490 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-3.09%-1.54%-4.95%-20.93%-24.31%
Mesoblast Limited stock logo
MESO
Mesoblast
-4.80%-7.07%-7.84%-23.33%-26.02%
ProKidney Corp. stock logo
PROK
ProKidney
-8.59%-23.56%-28.11%-17.90%-58.04%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-5.53%-13.31%-20.56%-23.49%+57.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$31.32
-3.1%		$33.08
$22.24
▼
$46.00
$1.93B0.631.20 million shs952,660 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$13.28
-4.8%		$15.65
$12.94
▼
$21.50
$1.81B2.14237,865 shs615,686 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.33
-8.6%		$1.68
$1.30
▼
$3.48
$439.88M1.771.72 million shs1.66 million shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$120.30
-5.5%		$145.44
$68.96
▼
$161.38
$1.83B-0.27250,323 shs179,490 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-3.09%-1.54%-4.95%-20.93%-24.31%
Mesoblast Limited stock logo
MESO
Mesoblast
-4.80%-7.07%-7.84%-23.33%-26.02%
ProKidney Corp. stock logo
PROK
ProKidney
-8.59%-23.56%-28.11%-17.90%-58.04%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-5.53%-13.31%-20.56%-23.49%+57.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.55
Moderate Buy$41.5032.50% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.33
Hold$39.00193.67% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00802.26% Upside
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2.94
Moderate Buy$209.7974.39% Upside

Current Analyst Ratings Breakdown

Latest PROK, PVLA, MESO, and AGIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$226.00
10/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform
10/12/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$270.00 ➝ $246.00
10/9/2026
Mesoblast Limited stock logo
MESO
Mesoblast
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/7/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$39.00 ➝ $37.00
10/6/2026
ProKidney Corp. stock logo
PROK
ProKidney
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/25/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/24/2026
Mesoblast Limited stock logo
MESO
Mesoblast
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/21/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D)
9/21/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$240.00
9/21/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$46.00 ➝ $50.00
(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$54.03M34.61N/AN/A$20.46 per share1.53
Mesoblast Limited stock logo
MESO
Mesoblast
$120.25M14.34N/AN/A$4.38 per share3.03
ProKidney Corp. stock logo
PROK
ProKidney
$890K451.78N/AN/A($3.36) per share-0.40
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M40.49N/AN/A$2.36 per share50.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$412.78M-$7.01N/AN/AN/A-418.24%-35.67%-33.06%11/5/2026 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$57.50MN/AN/A36.89N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$41.72M-$4.83N/AN/AN/AN/A-47.84%-38.33%11/10/2026 (Estimated)

Latest PROK, PVLA, MESO, and AGIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$1.7439N/AN/AN/A$0.02 millionN/A
11/9/2026Q3 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.12N/AN/AN/A$0.13 millionN/A
11/5/2026Q3 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.24N/AN/AN/A$51.95 millionN/A
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
8/4/2026Q2 2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$1.17-$1.52-$0.35-$1.52N/AN/A
7/31/2026Q4 2026
Mesoblast Limited stock logo
MESO
Mesoblast
N/A-$0.0660N/A-$0.0660N/A$34.45 million
7/30/2026Q2 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.65-$1.69-$0.04-$1.69$26.40 million$44.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
10.22
9.79
Mesoblast Limited stock logo
MESO
Mesoblast
0.19
2.43
2.09
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
21.18
21.18

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
5.40%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
17.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
54059.70 million56.48 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
108129.88 million105.46 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
231302.32 million181.91 millionOptionable
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2914.41 million11.93 millionN/A

Recent News About These Companies

Brokers Offer Predictions for PVLA Q1 Earnings
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31127129
William Blair Initiates Coverage on Palvella Therapeutics With Outperform Rating
October 16 at 1:51 PM  |  marketscreener.comM
Palvella Therapeutics (NASDAQ:PVLA) Stock: Insider George Jenkins Sells 13,152 Shares
October 16 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31125211
What is HC Wainwright's Estimate for PVLA FY2027 Earnings?
October 16 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31124026
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Biotech Gem with Nearly 87% Potential Upside
October 15 at 9:05 AM  |  directorstalkinterviews.comhttps://www.directorstalkinterviews.com/palvella-therapeutics-inc-pvla-stock-analysis-a-biotech-gem-with-nearly-87-potential-upside/4121266499
What is HC Wainwright's Estimate for PVLA Q1 Earnings?
October 15 at 7:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-pvla-q1-earnings-2026-10-15/
Palvella Therapeutics Announces Pediatric Analyses of QTORIN Rapamycin Showing Improvements in Rare Vascular Malformations
October 15 at 7:51 AM  |  quiverquant.comQ
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
October 15 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381533/0/en/palvella-therapeutics-to-present-phase-3-selva-and-phase-2-toiva-results-along-with-new-pediatric-analyses-at-2026-pedra-annual-conference.html
Palvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 7,174 Shares of Stock
October 15 at 5:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pvla-insider-buying-and-selling-2026-10-15/
Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in Stock
October 14 at 9:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-palvella-therapeutics-nasdaq-pvla-director-sells-93520264-in-stock-2026-10-14/
Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in Stock
October 14 at 9:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-palvella-therapeutics-nasdaq-pvla-director-sells-175829088-in-stock-2026-10-14/
What is HC Wainwright's Forecast for PVLA FY2027 Earnings?
October 14 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-forecast-for-pvla-fy2027-earnings-2026-10-14/
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379571/0/en/palvella-therapeutics-to-participate-in-the-chardan-10th-annual-healthcare-conference.html
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
October 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/palvella-therapeutics-announces-three-poster-presentations-highlighting-new-data-in-microcystic-lymphatic-malformations-and-dsap-at-fall-clinical-dermatology-2026-1036616251
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Target Lowered at HC Wainwright
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110315
Palvella Therapeutics (NASDAQ:PVLA) Given New $246.00 Price Target at HC Wainwright
October 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-palvella-therapeutics-nasdaq-pvla-given-new-24600-price-target-at-hc-wainwright-2026-10-12/
Palvella Therapeutics, Inc. Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For QTORIN? Rapamycin
September 29, 2026  |  marketscreener.comM
Palvella Therapeutics - U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
September 29, 2026  |  marketscreener.comM
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950711-palvella-therapeutics-fda-handholding-makes-the-regulatory-story-stronger
Palvella Therapeutics Wins Additional US FDA Grant Funding for Rare Skin Disease Drug
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/palvella-therapeutics-wins-additional-us-121715803.html
Palvella Receives Additional FDA Funding For QTORIN Rapamycin In Lymphatic Malformations
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694313/palvella-receives-additional-fda-funding-for-qtorin-rapamycin-in-lymphatic-malformations.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$31.32 -1.00 (-3.09%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$31.32 0.00 (0.00%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$13.28 -0.67 (-4.80%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$13.30 +0.02 (+0.11%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.33 -0.13 (-8.59%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.32 -0.02 (-1.13%)
As of 10/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$120.30 -7.04 (-5.53%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$120.00 -0.30 (-0.25%)
As of 10/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas